C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD)
暂无分享,去创建一个
[1] S. Kersten,et al. Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.
[2] Wang-Soo Lee,et al. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions , 2015, PPAR research.
[3] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[4] J. Deisenhofer,et al. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.
[5] Thomas P Cappola,et al. Transcriptomic biomarkers of cardiovascular disease. , 2012, Progress in cardiovascular diseases.
[6] D. Bell. Beta-cell rejuvenation with thiazolidinediones. , 2003, The American journal of medicine.
[7] Chris T. A. Evelo,et al. CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis , 2013, PloS one.
[8] Jianguo Xia,et al. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.
[9] Jonathan Chaffer,et al. jQuery Reference Guide: A Comprehensive Exploration of the Popular JavaScript Library , 2007 .
[10] C. Guillemette,et al. The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene* , 2003, The Journal of Biological Chemistry.
[11] M. Fresno,et al. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. , 2006, The Biochemical journal.
[12] Joana A. Vidigal,et al. The biological functions of miRNAs: lessons from in vivo studies. , 2015, Trends in cell biology.
[13] J. Hengstler,et al. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes , 2016, Archives of Toxicology.
[14] Alan F. Scott,et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..
[15] B. Tian,et al. RNA‐Seq methods for transcriptome analysis , 2017, Wiley interdisciplinary reviews. RNA.
[16] Danish Sayed,et al. MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy , 2007, Circulation research.
[17] D. Bell. β-Cell rejuvenation with thiazolidinediones , 2003 .
[18] Hsien-Da Huang,et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..
[19] Michael Darsow,et al. ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..
[20] Michael Müller,et al. Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.
[21] Ramon Luengo-Fernandez,et al. European Cardiovascular Disease Statistics 2017 , 2012 .
[22] Euan A Ashley,et al. Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.
[23] B. Staels,et al. Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.
[24] Astrid Gall,et al. Ensembl 2018 , 2017, Nucleic Acids Res..
[25] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[26] J. Hou,et al. Circulating MicroRNA Profiles Differ between Hyperglycemia and Euglycemia in Coronary Heart Disease Patients , 2017, BioMed research international.
[27] Artemis G. Hatzigeorgiou,et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..
[28] Bernhard Mlecnik,et al. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data , 2013, Bioinform..
[29] 任艳,et al. 胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .
[30] R. Murugesan,et al. CardioGenBase: A Literature Based Multi-Omics Database for Major Cardiovascular Diseases , 2015, PloS one.
[31] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[32] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[33] Hui Liu,et al. CADgene: a comprehensive database for coronary artery disease genes , 2010, Nucleic Acids Res..
[34] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[35] A. Yashin,et al. Heritability of death from coronary heart disease: a 36‐year follow‐up of 20 966 Swedish twins , 2002, Journal of internal medicine.
[36] Ronald Aylmer Sir Fisher,et al. 224A: Answer to Question 14 on Combining independent tests of significance. , 1948 .
[37] R. Deberardinis,et al. Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.
[38] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[39] W. Wahli,et al. PPARα governs glycerol metabolism , 2004 .
[40] J. Gardin,et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. , 1994, American journal of epidemiology.
[41] Antje Chang,et al. BRENDA in 2017: new perspectives and new tools in BRENDA , 2016, Nucleic Acids Res..
[42] Ankit Sharma,et al. In-Cardiome: integrated knowledgebase for coronary artery disease enabling translational research , 2017, Database J. Biol. Databases Curation.
[43] J. Auwerx,et al. Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. , 1992, Journal of lipid research.
[44] Giovanni Scardoni,et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data , 2012, Bioinform..
[45] A. Khera,et al. Genetics of coronary artery disease: discovery, biology and clinical translation , 2017, Nature Reviews Genetics.
[46] Alan D. Lopez,et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.
[47] Ana Kozomara,et al. miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..
[48] S. J. Lee,et al. Metabolite Changes Signal Genetic Regulatory Mechanisms for Robust Cell Behavior , 2014, mBio.
[49] E. Fisher,et al. Fibrate Therapy: An Update , 2008, Cardiology in review.
[50] M. Mann,et al. Quantitative, high-resolution proteomics for data-driven systems biology. , 2011, Annual review of biochemistry.
[51] Chris T. A. Evelo,et al. WikiPathways: building research communities on biological pathways , 2011, Nucleic Acids Res..
[52] L. Berkman,et al. Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.
[53] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[54] C. Hermenegildo,et al. MicroRNA as Crucial Regulators of Gene Expression in Estradiol-Treated Human Endothelial Cells , 2018, Cellular Physiology and Biochemistry.
[55] Anjali J. Koppal,et al. Supplementary data: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites , 2010 .
[56] Michael Lehrke,et al. The many faces of PPARgamma. , 2005, Cell.
[57] D. Cooper,et al. Impact of brief exercise on circulating monocyte gene and microRNA expression: Implications for atherosclerotic vascular disease , 2014, Brain, Behavior, and Immunity.
[58] Minoru Kanehisa,et al. KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..
[59] B. Staels,et al. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. , 2004, Molecular endocrinology.
[60] K. Lage,et al. Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease , 2015, PLoS genetics.
[61] J. Garland. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[62] H. Husi,et al. Establishment of a integrative multi-omics expression database CKDdb in the context of chronic kidney disease (CKD) , 2017, Scientific Reports.
[63] Gary D. Bader,et al. GeneMANIA Prediction Server 2013 Update , 2013, Nucleic Acids Res..
[64] C. Bauters,et al. [Pathophysiology of coronary artery disease]. , 2008, La Revue du praticien.
[65] A. Oyekan. PPARs and their Effects on the Cardiovascular System , 2011, Clinical and experimental hypertension.
[66] Martin McKee,et al. Priority actions for the non-communicable disease crisis , 2011, The Lancet.
[67] Núria Queralt-Rosinach,et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes , 2015, Database J. Biol. Databases Curation.
[68] G. Hansson,et al. The immunology of atherosclerosis , 2017, Nature Reviews Nephrology.
[69] M. Lazar,et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.
[70] B. Staels,et al. The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α , 2004 .
[71] Damian Szklarczyk,et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..
[72] Renata C. Geer,et al. The NCBI BioSystems database , 2009, Nucleic Acids Res..
[73] Michael Lehrke,et al. The Many Faces of PPARγ , 2005, Cell.
[74] S. Blankenberg,et al. Blood-based gene expression tests: promises and limitations. , 2013, Circulation. Cardiovascular genetics.
[75] B. Staels,et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.
[76] P. Sime,et al. PPARγ and the Innate Immune System Mediate the Resolution of Inflammation , 2015, PPAR research.
[77] John R Yates,et al. Proteomics by mass spectrometry: approaches, advances, and applications. , 2009, Annual review of biomedical engineering.
[78] S. Humphries,et al. Progression of Carotid Intima-Media Thickness as Predictor of Vascular Events: Results from the IMPROVE Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[79] Aldons J. Lusis,et al. Atherosclerosis : Vascular biology , 2000 .
[80] M. Fornage,et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.
[81] H. Iso. Lifestyle and cardiovascular disease in Japan. , 2011, Journal of atherosclerosis and thrombosis.
[82] R. Beaglehole,et al. Priority actions for the non-communicable disease crisis – Authors' reply , 2011, The Lancet.
[83] F. Lönnqvist,et al. Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1 , 2005, Diabetologia.
[84] T. Kurtz,et al. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system , 2004, Journal of hypertension.
[85] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[86] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[87] Christian M. Metallo,et al. Understanding metabolic regulation and its influence on cell physiology. , 2013, Molecular cell.
[88] J. Auwerx,et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. , 2012, European heart journal.
[89] Jasmine Chen,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[90] Christopher K. Glass,et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.
[91] M. Panchatcharam,et al. PPARγ and Its Role in Cardiovascular Diseases , 2017, PPAR research.
[92] Pornpimol Charoentong,et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..
[93] P. Libby,et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.
[94] R. Evans,et al. Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.
[95] Ibrahim Emam,et al. ArrayExpress update—from an archive of functional genomics experiments to the atlas of gene expression , 2008, Nucleic Acids Res..
[96] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[97] F. Hirsch,et al. Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. , 2015, Biomarkers in medicine.
[98] Frank J. Gonzalez,et al. Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.
[99] B. Staels,et al. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. , 2000, The Journal of biological chemistry.
[100] Yifeng Chai,et al. Cardiovascular Disease Chemogenomics Knowledgebase-guided Target Identification and Drug Synergy Mechanism Study of an Herbal Formula , 2016, Scientific Reports.
[101] Nobel C. Zong,et al. Integration of Cardiac Proteome Biology and Medicine by a Specialized Knowledgebase , 2013, Circulation research.
[102] A. Lamond,et al. Multidimensional proteomics for cell biology , 2015, Nature Reviews Molecular Cell Biology.
[103] W. Wahli,et al. PPARalpha governs glycerol metabolism. , 2004, The Journal of clinical investigation.
[104] E. Suchman,et al. The American Soldier: Adjustment During Army Life. , 1949 .
[105] N. Marx,et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.
[106] C. Guillemette,et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. , 2003, The Journal of biological chemistry.
[107] F. Pontén,et al. The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.